Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Ven... ( 70% Elimination Of The Deadly Superb...)

Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers

Date:6/17/2008

70% Elimination Of The Deadly Superbug Provides Hope For Global Caregivers

PRINCETON, N.J., June 17 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that its key product, MEDIHONEY(TM) Wound & Burn Dressing with Active Leptospermum Honey, has been found in a large randomized controlled clinical trial to significantly reduce the presence of methicillin-resistant Staphylococcus aureus (MRSA) in chronic wounds. The finding was published in the June 2008 issue of The Journal of Wound Care.

MRSA continues to dominate global headlines as a formidable hospital-acquired infection, killing thousands of patients each year and becoming a huge burden on healthcare costs. The number of hospital admissions for MRSA has increased rapidly over the last decade, with a 300% increase in 2005 over that of 2000, and a 1000% increase over that of 1995. Conservative estimates suggest a global figure of up to 53 million people carrying MRSA. The bacteria is resistant to such common antibiotics as methicillin, amoxicillin, penicillin, and oxacillin, and is quick to adapt to new ones. Historically, MRSA has been most common among people with weak immune systems living in either hospitals or long-term care centers. However, it has been increasingly present in healthy people, giving rise to community-acquired MRSA.

Commenting on the publication, CEO Ed Quilty stated, "This study was presented last year at the European Wound Management Association, and we are pleased that the work has been recognized in such a well-regarded peer reviewed wound care journal serving the global market. MRSA, which is now reaching out beyond the walls of hospitals and nursing homes into the general community, claims more lives than AIDS in certain countries. MEDIHONEY's ability to eradicate this superbug, while also helping chronic wounds to progress towards healing, makes it a truly unique product in the field
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
2. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
3. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
5. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
6. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
7. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
11. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder

Post Your Comments:

Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Ven...( 70% Elimination Of The Deadly Superb...),Health